AZN - Mineralys Therapeutics: A Story To Keep An Eye On

2024-03-18 07:04:31 ET

Summary

• Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels.
• The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension.
• Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease.
• A full investment analysis follows in the paragraphs below.

Today, we put hypertension concern Mineralys Therapeutics, Inc. ( MLYS ) in the spotlight. The stock is off slightly since its public debut in February of 2023, owing to a lack of market moving news regarding its sole asset lorundrostat, but that could change beginning in 2H24. With three readouts coming over the next two years, but some clinical rivals to surmount, the insider buying on the recent private placement merited a deeper dive. An analysis follows below....

For further details see: